The quantification of residual plasmatic ADAMTS13 activity in congenital thrombotic thrombocytopenic purpura (TTP) patients is constrained by limitations in the sensitivity and reproducibility of commonly used assays at low levels of ADAMTS13 activity, blunting efforts to establish genotype-phenotype associations in the disease. In this study, the residual plasmatic activity of ADAMTS13 was centrally measured by SELDI-TOF mass spectrometry (limitof-detection=0.5%) in 29 patients with congenital TTP. The results were used to study the correlations between ADAMTS13 genotype, residual plasmatic activity and the clinical phenotype of the disease. ADAMTS13 activity above 0.5% was measured in 26 (90%) patients and lower levels of activity were associated with earlier age of onset, more frequent recurrences and prescription of fresh frozen plasma prophylaxis. At receiver operating characteristic curve analysis, activity levels of less than 2.7% were discriminative of severe disease, i.e., age of onset <18 years, annual rate of TTP episodes >1, and use of prophylaxis. Mutations affecting the highly-conserved N-terminal domains of the protein were associated with lower residual ADAMTS13 activity and more severe disease phenotype in an allelic-dose dependent manner. Our results show that residual ADAMTS13 activity is associated with the severity of clinical phenotype in congenital TTP and provide insights into genotype-phenotype relationships.
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Introduction
Congenital thrombotic thrombocytopenic purpura (TTP) (also known as Upshaw-Schulman syndrome, OMIM #274150) is a rare, recessively inherited thrombotic microangiopathy. The disease is characterized by the congenital severe deficiency of ADAMTS13 plasmatic activity caused by mutations in the ADAMTS13 gene. [1] [2] [3] [4] [5] [6] The phenotype of congenital TTP is variable in its severity. Some patients present with the disease in the neonatal period, while others have an adult disease-onset. Moreover, patients may experience only a few isolated episodes of TTP, whereas others have frequent recurrences leading to the prescription of fresh frozen plasma (FFP) prophylaxis. [5] [6] [7] [8] A recent review of the ~100 published cases of congenital TTP showed that patients carrying the same ADAMTS13 gene mutations develop their first disease episode at a similar age. 9 This observation suggests that different ADAMTS13 mutations may influence the severity of clinical phenotype, probably by determining different levels of residual plasmatic activity of ADAMTS13. However, the quantification of residual ADAMTS13 activity in congenital TTP patients is blunted by limitations in the analytical sensitivity and performance in the low-end of ADAMTS13 activity distribution (i.e. activity below 6%) of the commonly used ADAMTS13 activity assays. [10] [11] [12] [13] A recently described method, based on surface-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) mass spectrometry, is able to accurately measure ADAMTS13 plasmatic activity with high analytical sensitivity (limit of detection of 0.5%, i.e. 5-to 10-fold higher sensitivity than most commercially available assays). 14, 15 In this study, we measured the residual activity of ADAMTS13 by SELDI-TOF mass spectrometry in a cohort of 29 patients with congenital TTP and studied the relationships between ADAMTS13 genotype, residual plasmatic activity and the clinical phenotype of the disease.
Patients and Methods

Patients
Patients registered between 2000 and 2010 in four European TTP registries, the Milan TTP registry (Milan, Italy), 16, 17 the Southeast England TTP registry (London, UK) 18 , the International Registry for HUS and TTP (Bergamo, Italy), 19 the TMA Registry of the French Reference Center for the management of thrombotic microangiopathies (Paris, France), 20 were evaluated for study eligibility. Inclusion criteria were: (a) history of at least one episode of TTP (defined by the presence of thrombocytopenia and microangiopathic Coombs negative hemolytic anemia with signs of red blood cell fragmentation), (b) severe deficiency of ADAMTS13 with activity <6%, measured by collagen binding assay 10 or fluorescence resonance energy transfer 11 , (c) absence of anti-ADAMTS13 autoantibodies, searched for by western blotting 21 or ELISA 17-20 (d) documented mutations of ADAMTS13 after sequencing of the protein coding area of the gene by PCR and Sanger sequencing (e) availability of 100 µL of citrated plasma collected during remission at least 20 days from the last infusion of FFP or any other blood-derived products. A total of 29 patients were included in the study (Milan, n=12; UK, n=7; Bergamo, n=5; France, n=5). The disease histories of 16 patients had already been described elsewhere, 9, [22] [23] [24] [25] [26] [27] [28] [29] whereas 13 are presented here for the first time. For each patient, phenotypic data were retrieved including: age at last follow up and sex, ethnicity, age at first TTP episode (in order to minimize misclassification, the age of onset was adjudicated on the basis of the first disease episode that required FFP infusion), lifetime and annual frequency of TTP episodes, use of regular FFP prophylaxis, history of neonatal jaundice or thrombocytopenia and presence of renal or neurological damage, defined as presence of chronic renal failure and persistence of neurological deficit during remission. Individual clinical and genetic information are reported in Supplementary Material S1. The study was approved by the Institutional Review Boards of the participating centers and all subjects gave informed consent.
Measurement of ADAMTS13 activity
All samples were shipped in dry ice to the Hematology laboratory at Department of Pathology, Ohio State University, Columbus, OH (USA) for centralized measurement. ADAMTS13 activity was determined in this central laboratory using a SELDI-TOF mass-spectrometer-based method. 14 The laboratory personnel was unaware of the clinical features of the patients. ADAMTS13 activity was determined by mixing patient plasma with the enzyme substrate VWF73 containing a 6XHis tag. The cleavage product was enriched by IMAC ProteinChip and then quantified using SELDI-TOF mass spectrometry. 14, 15 An internal control was generated by cleaving recombinant-6×His-tagged human VWF73 by PreScissionTM Protease (Amersham Biosciences), as described before. 14 Briefly, 10 µL of patient plasma were mixed with 30 µL buffer (5 mM Tris HCl, 5 mM NaCl, 1 mM BaCl2, pH 7.5) containing 2.5 µg of 6×His tagged human VWF73 (D1596-R1668). The cleavage reaction was performed for 16 hours at 37 °C and then terminated by boiling the samples at 100 °C for 2 min.
Each experiment included a standard curve performed under identical conditions except that the plasma sample was replaced by pooled normal plasma (PNP) diluted at 7.5%, 5%, 3.5%, 2.5%, 1.5%, 1% and 0.5% in 100 mM NaCl containing 0.1% bovine serum albumin (BSA) (Figure 1 ). Following the cleavage reaction, 40 µL internal control (0.01 µg/ µL) was mixed with 35 µL reaction sample from each patient on the corresponding IMAC ProteinChip spot. After incubation for 30 min at room temperature with constant shaking, each spot was washed five times with 200 µL of washing buffer. This was followed by one quick wash with 1 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), pH 7.0. Finally, 1 µL of energy absorbing molecule (EAM) solution (100% saturated sinapinic acid in 50% acetonitrile and 0.5% trifluoroacetic acid) was added to each spot. The cleavage products on the IMAC ProteinChips were analyzed by PCS4000 SELDI-TOF mass spectrometer (Vermillion Inc). In order to evaluate the test reproducibility in the lower analytical range, two external controls (two TTP patients with their plasma samples aliquoted and frozen at -80C) were tested repeatedly over time and by different operators. The ADAMTS13 activity levels obtained (mean ± 2SD) for these two patients were 1.8%±0.2% and 4.8%±0.8%, respectively, indicating good test reproducibility.
The coefficient of variation for those two controls was 6.8% and 7.8%, respectively.
Mutation analysis and annotation
In keeping with the Human Genome Variation Society (HGVS) instructions, nucleotide numbering for reported mutations refers to cDNA numbering with the A of the ATG codon numbered as +1. According to new instructions, stop codons were designed as "*" instead of "X". NM_139025.3 was used as a reference for nucleotide changes. NP_620596.2 was used as protein reference sequence. The review of ADAMTS13 mutations associated with congenital TTP was based on published articles found through searches on PubMed (updated to July 2011), using "ADAMTS13 mutation", "ADAMTS13 genotype", and "congenital thrombotic thrombocytopenic purpura" as queries. Polymorphisms of ADAMTS13 were searched for on dbSNP. As suggested by the HGVS, the accuracy of nucleotide change for reported mutations was verified by Mutalyzer 
Genotype risk classification
To study the relationship between mutation localization and clinical phenotype, a genotype classification was constructed considering N-terminal mutations as a risk factor for more severe disease. N-terminal mutations were mutations affecting ADAMTS13 aminoacid 1-714, C-terminal mutatons were mutations affecting aminoacid 715-1427. One point was added to the score for each missense mutation affecting the N-terminal of the ADAMTS13 protein. Mutation and genotype score classification data for all patients are provided in the Supplementary Material S1.
Statistical analysis
Descriptive statistics are presented as medians (interquartile range [IQR]) and
percentages. Bivariate associations between categorical variables were done using the Fisher's exact test. Linear and logistic regression analysis were used to calculate estimates and 95% confidence intervals (CI) of the associations between plasmatic ADAMTS13 activity, the genotype risk score and clinical outcomes.
Receiver operating characteristic (ROC) curve analysis was used to determine the ADAMTS13 activity levels that could discriminate patients who had severe clinical outcomes with the highest sum of sensitivity and specificity.
Results
Patients characteristics and SELDI-TOF based measurement of ADAMTS13 activity
The features of the 29 patients with congenital TTP included in this study are presented in Table 1 . Residual plasmatic activity of ADAMTS13 was measured in a central laboratory on samples collected during remission at least 20 days after the last infusion of FFP or other blood-derived products. Measurements were carried out in two duplicates of the same sample, the median difference in the measurements between the two duplicates being 0.13% (IQR: 0.43%). Raw data on duplicate measurement results are available in the Supplementary Material S1.
A total of 26 patients (90%) had measurable residual activity of ADAMTS13, whereas three patients had activity <0.5%. Activity was below 10% in all patients confirming the previous diagnosis of severe deficiency of ADAMTS13. The median plasmatic ADAMTS13 activity was 3.08% (IQR: 4.17%; range: <0.5-6.77%). In a few patients with multiple remission samples available for measurement, residual ADAMTS13 activity was similar in the different samples (Supplementary Material S3). Table 2 . Support for the causal role of the newly identified ADAMTS13 mutations was sought for by annotation on databases of common genetic variation and sequencing of the ADAMTS13 gene in 99 healthy Caucasian individuals. None of the mutations were present in dbSNP131, in the 1000Genomes database or in 198 alleles from 99 controls, enabling us to exclude that the identified variants were common polymorphisms. All the novel missense mutations were also annotated on SIFT and Polyphen 2 software for the prediction of the functional effect of protein changes (predicted to be damaging vs predicted to be benign) ( Table 2) . As a critical test of the utility of these annotations, we determined their ability to 
Association between residual ADAMTS13 activity and the severity of clinical phenotype in congenital TTP
The associations between residual ADAMTS13 activity and the phenotypic features of congenital TTP are outlined in Table 3 . A lower residual ADAMTS13 activity was associated with earlier age of onset ( Figure 2A ). Lower levels of plasmatic ADAMTS13 were also associated with a higher annual rate of TTP episodes ( Figure 2B ) and with higher odds of regular FFP prophylaxis prescription. We used receiver operating characteristic curve analysis to determine the levels of residual ADAMTS13 activity that best discriminated patients at risk for unfavorable clinical endpoints (i.e. age of onset below 18 years, annual rate of TTP episodes greater than 1 and prescription of FFP prophylaxis). An ADAMTS13 activity <2.74% discriminated patients who had a disease onset below 18 years and those who had prescription of regular FFP prophylaxis, whereas an activity <1.61% discriminated patients who had an annual rate of TTP episodes greater than 1 ( Table 4 ).
Relationships between ADAMTS13 mutations, residual plasmatic activity of ADAMTS13 and clinical outcomes of congenital TTP
Because patients with the same ADAMTS13 genotype were found to have similar age of onset, 9 we hypothesized that ADAMTS13 gene mutations could influence the clinical phenotype of congenital TTP, by determining different patterns of residual ADAMTS13 activity. We plotted ADAMTS13 genotypes that occurred more than once in the study cohort against the residual ADAMTS13 activity and the age of onset of the corresponding patients ( Figure 3 ). A clustering of both age of onset and residual ADAMTS13 activity in patients with the same genotype was observed, suggesting that ADAMTS13 mutations influence both the amount of residual ADAMTS13 activity and the clinical features of the disease. In order to identify the relationships between specific ADAMTS13 mutations and the clinical features of congenital TTP we studied the type and distribution of congenital-TTP-causing ADAMTS13 mutations on the ADAMTS13 protein domains. Including the 8 novel mutations, 121 mutations of ADAMTS13 have been described to date in congenital TTP patients. Of these, 62 (51%) are missense. Notably, 76% (n=47) of the missense mutations of ADAMTS13 described in TTP patients localize in the N-terminal of the protein (binomial probability, p=2.01x10 -5 ), which is the area with the highest degree of evolutionary conservation 9 and where the domains necessary for ADAMTS13 catalytic activity are located. 30, 31 In contrast to this, missense single nucleotide polymorphisms (SNPs) of ADAMTS13 included in dbSNP131, which are likely not all to be related to disease, do not show evidence of skewed distribution (p=0.14). We also evaluated the evolutionary conservation at the sites of all On linear regression analysis, there was a negative association between the genotype severity score and age of disease onset ( Figure 5B ). Moreover, there was a positive association between genotype severity and the annual rate of TTP episodes ( Figure 5C ). Results remained unchanged when patients carrying truncating mutations at the C-terminal domains were excluded form the analysis.
Discussion
A new SELDI-TOF mass spectrometry-based method was used to measure the residual plasmatic activity of ADAMTS13 in 29 congenital TTP patients, with the aim of investigating the relationships between ADAMTS13 genotype, residual plasmatic activity and the clinical phenotype of the disease. Our main study findings were the following: (a) a residual plasmatic activity of ADAMTS13 was measurable by SELDI-TOF mass-spectrometry in 90% of the study participants; activity only in few patients. Because many of these studies adopted immunoblotting and collagen binding assay for the identification of severe ADAMTS13 deficiency, this result is not surprising in light of the high limit of detection and scarce reproducibility of these assays at low ADAMTS13 concentrations. 12, 13 Recently, a Japanese group reported a large cohort of congenital TTP patients in whom ADAMTS13 was measured by an ELISA method with a reportedly low limit of detection (i.e, 0.5%), finding a residual activity only in a minority of patients. Because limits of detection are calculated against different calibration curves with different reference samples, a formal comparison of the limits of detection of that assay with ours cannot be made unless both assays are tested against a common 'standard'. However, we note that several proofs of the reliability and validity of our measurements were provided in this study, arguing against random or biased results. First, a calibration curve using calibrators with concentrations of ADAMTS13 <10% was calculated before each assay, showing the linearity of the method at very low concentrations (see Figure 1 ). Second, repeated measurements on the same sample (including duplicate measurements and two external controls repeated over time by different operators) and multiple samples of the same patient consistently produced similar activity results. Third, the detection method of the assay used in this study (i.e. mass spectrometry) is considered to be the 'gold standard' for protein detection, providing high analytical sensitivity and specificity for very tiny amounts of cleavage products. Decreasing levels of residual ADAMTS13 activity were associated with earlier age of onset, more frequent disease recurrences and prescription of FFP prophylaxis to prevent further recurrences. These results are consistent with the view that congenital TTP patients with a higher residual plasmatic activity of ADAMTS13 are protected from disease onset until they come across a strong challenge to their fragile ADAMTS13-VWF balance (e.g., pregnancy, which is often a triggering factor of TTP in women with adult-onset disease), whereas patients with low or no residual activity are vulnerable to environmental challenges, developing early-onset disease and frequent recurrences that prompt caring physicians to prescribe FFP prophylaxis. We identified levels below 1.6-2.7% as levels of ADAMTS13 activity predictive of clinical endpoints of disease severity. An activity of ADAMTS13 below these levels identified patients with early disease-onset, frequent recurrences and the need for preventive FFP infusion with high specificity, suggesting that patients with low residual ADAMTS13 activity are unlikely to have mild disease.
In this study, we also reported 8 novel mutations of ADAMTS13 associated with congenital TTP. A detailed analysis of the annotation, functional consequences and distribution on ADAMTS13 of these novel and of previously reported mutations revealed that mutations in the highly conserved N-terminal domains of ADAMTS13, which have been shown to be required for the catalytic activity of this enzyme, are more likely to be associated with congenital TTP, lower residual ADAMTS13 activity and earlier age of disease onset than those of C-terminal domains. The association of ADAMTS13 genotype with the clinical phenotype was attenuated by adjusting for ADAMTS13 plasmatic activity, confirming that ADAMTS13 genotype influences the disease severity at least in part through the residual plasmatic activity of ADAMTS13. Limitations of this study include that individual ADAMTS13 activity was measured once for the majority of patients and that clinical outcomes were ascertained some years after their occurrence.
Both would have led to random misclassification -since neither mutations nor levels were known at the time -and hence an underestimation of actual differences. Serial measurements of ADAMTS13 would have been interesting, but were not feasible in this study with patients from different regions of different continents. However, by measuring ADAMTS13 in more than one sample of several patients we showed that residual ADAMTS13 activity during remission is likely constant in a given patient. Since the prevalence of congenital TTP is estimated to be ~1/1 million, 32 prospective studies will rarely be feasible. In addition, the clinically relevant endpoints of the study (i.e. age of onset, rate of episodes, use of FFP prophylaxis) can be considered "hard" endpoints, unlikely to be misclassified. To further minimize subjectivity in age of onset definition, we required that the first disease episode warranting plasma infusion be considered as the first episode of the disease.
In conclusion, we found that residual ADAMTS13 activity is associated with the phenotype severity of congenital TTP and that mutations affecting the 
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Figures
Figure 2.
Relationship between residual ADAMTS13 activity and clinical features of congenital TTP. Panel A: association between residual ADAMTS13 deficiency and age of disease onset in 29 patients with congenital TTP at linear regression analysis. Only a few outliers were detected. A patient from the Milan cohort with adult age of onset and residual activity below 2.74% and 3 from the French cohort with neonatal onset and activity above 2.74%. Panel B: association between residual ADAMTS13 deficiency and the annual rate of TTP episodes.
Figure 3.
Relationship between ADAMTS13 genotype, residual activity and age of disease onset. Age of disease onset and residual ADAMTS13 activity in multiple patients carrying the same mutations of ADAMTS13. A clustering of both the age of onset and the plasmatic activity of ADAMTS13 can be observed for patients with a given ADAMTS13 genotype. For each patient ADAMTS13 activity (triangle) and age of onset (circle) are aligned. . Association between genotype severity score, plasmatic activity of ADAMTS13, age of disease onset and annual rate of TTP episodes. Increasing severity in the genotype score (i.e. an increasing number of N-terminal mutations; 'mild genotype' = 2 C-terminal mutations, 'moderate genotype' = 1 C-and 1 Nterminal mutations; 'severe genotype' = 2 N-terminal mutations) was associated with lower plasmatic activity of ADAMTS13 (Panel A), earlier age of onset (Panel B) and higher annual rate of TTP episodes (Panel C). Ben, predicted benign; Prod, predicted to be probably damaging. 
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